EMPRACET W/ CODEINE PHOSPHATE #4 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Empracet W/ Codeine Phosphate #4, and when can generic versions of Empracet W/ Codeine Phosphate #4 launch?
Empracet W/ Codeine Phosphate #4 is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in EMPRACET W/ CODEINE PHOSPHATE #4 is acetaminophen; codeine phosphate. There are sixty-six drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the acetaminophen; codeine phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Empracet W/ Codeine Phosphate #4
A generic version of EMPRACET W/ CODEINE PHOSPHATE #4 was approved as acetaminophen; codeine phosphate by WES PHARMA INC on June 27th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMPRACET W/ CODEINE PHOSPHATE #4?
- What are the global sales for EMPRACET W/ CODEINE PHOSPHATE #4?
- What is Average Wholesale Price for EMPRACET W/ CODEINE PHOSPHATE #4?
Summary for EMPRACET W/ CODEINE PHOSPHATE #4
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Patent Applications: | 4 |
| DailyMed Link: | EMPRACET W/ CODEINE PHOSPHATE #4 at DailyMed |
US Patents and Regulatory Information for EMPRACET W/ CODEINE PHOSPHATE #4
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | EMPRACET W/ CODEINE PHOSPHATE #4 | acetaminophen; codeine phosphate | TABLET;ORAL | 083951-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
